BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

  July 27, 2026

   · 

  5 min read
• Press Releases

  CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

  July 27, 2026

   · 

  8 min read
• Press Releases

  MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

  July 27, 2026

   · 

  11 min read
• Press Releases

  Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

  July 27, 2026

   · 

  3 min read
• Press Releases

  Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

  July 27, 2026

   · 

  10 min read
• Press Releases

  AstraZeneca results: H1 and Q2 2026

  July 27, 2026

   · 

  8 min read
• Press Releases

  Liberate Bio Appoints Steven H. Bernstein, M.D., as Chief Medical Officer to Advance In Vivo Cell Programming Toward the Clinic

  July 27, 2026

   · 

  4 min read
• Press Releases

  Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

  July 27, 2026

   · 

  11 min read
• Press Releases

  Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease

  July 27, 2026

   · 

  11 min read
• Press Releases

  Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt

  July 27, 2026

   · 

  5 min read